Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients

Journal of Pharmacy Practice

Volumn 24, Issue 2, 2011, Pages 216-222

  Crutchley, Rustin D ^a   Ma, Qing ^b   Sulaiman, Adel ^c,d   Hochreitter, Jill ^c   Morse, Gene D ^b,c,d  

^a UNIVERSITY OF HOUSTON   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ERIE COUNTY MEDICAL CENTER   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

atazanavir; pharmacodynamics; pharmacokinetics; protease inhibitors; therapeutic drug monitoring

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS DIDANOSINE; ABACAVIR PLUS LAMIVUDINE PLUS TENOFOVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR PLUS ZIDOVUDINE PLUS LAMIVUDINE; OMEPRAZOLE; PANTOPRAZOLE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; BODY MASS; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MONITORING; ETHNICITY; FEMALE; HEPATITIS B; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; PATIENT COMPLIANCE; PROSPECTIVE STUDY; QUALITY CONTROL; SAMPLE SIZE; TIME SINCE LAST DOSE; VIRUS LOAD;

EID: 79955566601     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010380923     Document Type: Article

References (26)

1. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
2. http://www.bms.com
3. Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006 ; 42 (8). 1189-1196
4. Boffito M, Back D, Hoggard PG, et al. Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS. 2003 ; 17 (7). 1107-1108 (Pubitemid 36549732)
5. Stahle L, Moberg L, Svensson JO, et al. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit. 2004 ; 26 (3). 267-270 (Pubitemid 38703012)
6. Lang T, Klein K, Fischer J. Extensive genetic polymorphism in the human CYP 2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001 ; 11 (5). 399-415 (Pubitemid 32656581)
7. Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naïve and experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007 ; 46 (4). 433-442 (Pubitemid 350098694)
8. Feldt T, Oette M, Kroidl A, et al. Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety. Eur J Med Res. 2005 ; 10 (1). 7-10 (Pubitemid 40305602)
9. Ray JE, Marriott D, Bloch MT, et al. Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. Br J Clin Pharmacol. 2005 ; 60 (3). 291-299 (Pubitemid 41224137)
10. Smith DE, Jeganathan S, Ray J. Atazanavir plasma concentrations vary significantly between patients and correlate with increased serum bilirubin concentrations. HIV Clin Trials. 2006 ; 7 (1). 34-38
11. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials. 2004 ; 5 (4). 201-205 (Pubitemid 39467966)
12. Burger D, Hugen P, Reiss P, et al. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naïve HIV-1-infected individuals. AIDS. 2003 ; 17 (8). 1157-1165 (Pubitemid 36667758)
13. Cleijsen RMM, Van de Ende ME, Kroon FP, et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. J Antimicrob Chemother. 2007 ; 60 (4). 897-900 (Pubitemid 47434275)
14. Winston A, Bloch M, Carr A, et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother. 2005 ; 56 (2). 380-387 (Pubitemid 41158529)
15. Higgins N, Zingman BS, Slish J, et al. Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. Am J Addict. 2007 ; 16 (6). 488-494 (Pubitemid 350223232)
16. Holland DT, DiFrancesco R, Conor JD, et al. Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring. Ther Drug Monit. 2006 ; 28 (3). 367-374 (Pubitemid 44314924)
17. Holland DT, DiFrancesco R, Stone J, et al. Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother. 2004 ; 48 (3). 824-831 (Pubitemid 38280331)
18. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006 ; 50 (11). 3801-3808 (Pubitemid 44684896)
19. Gonzalez de Requena D, Bonora S, Canta F. Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range [Abstract]. ; 2005 Twelfth Conference on Retroviruses and Opportunistic Infections ; 2005..
20. Slish J, Ma Q, Zingman BS, et al. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit. 2007 ; 29 (5). 560-565 (Pubitemid 47494052)
21. Ribera E, Azuaje C, Lopez RM, et al. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. AIDS. 2006 ; 20 (8). 1131-1139 (Pubitemid 43786101)
22. Ma Q, Brazeau D, Zingman BS, et al. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007 ; 8 (3). 1-9
23. Rodriguez-Novoa S, Martin-Carbonero L, Barreriro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007 ; 21 (1). 41-46 (Pubitemid 44912535)
24. Anderson PL, Lamba J, Aquilante CL, et al. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 ; 42 (4). 441-449 (Pubitemid 44050891)
25. Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther. 2005 ; 78 (6). 605-618 (Pubitemid 41773636)
26. Molto J, Santos JR, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice. Ther Drug Monit. 2007 ; 29 (5). 648-651 (Pubitemid 47494066)